Europe — EMA
Nuvaxovid
Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M, the active ingredient in Nuvaxovid, is a vaccine presented as a dose for intramuscular use.
Request sourcing
What is Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M?
Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M, the active ingredient in Nuvaxovid, is a vaccine presented as a dose for intramuscular use. It protects against COVID-19 in adults and older adults. GNH USA supplies Nuvaxovid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
GNH USA supplies Nuvaxovid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M used for?
Nuvaxovid is a recombinant protein COVID‑19 vaccine that stimulates immunity against SARS‑CoV‑2. - Prevention of COVID‑19: induces protective immunity in adults aged 18 years and and … - Booster vaccination: enhances immune response in individuals previously vaccinated with other COVID‑19 vaccines. - Protection ... ... .... .... ... ... ...
What are the side effects of Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M?
Common ... ... at … .
... …
What precautions apply to Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M?
Intro … .
t .... … "